TomoTherapy Appoints Roy Tanaka to Its Board of Directors

MADISON, Wis.--(Business Wire)--
TomoTherapy Incorporated (NASDAQ: TOMO), maker of the
TomoTherapy(R) Hi-Art(R) treatment system for advanced radiation
therapy, announced today the appointment of Roy T. Tanaka to its board
of directors. Tanaka, 60, brings to the TomoTherapy board 27 years of
operational leadership experience, including global market expansion.
He is newly retired from Biosense Webster, Inc., a Johnson & Johnson
company, where he most recently served as worldwide president.

"We welcome Roy to our board and look forward to tapping into his
experience leading a game-changing medical device company," said Fred
Robertson, TomoTherapy CEO. "Roy also brings varied skills and
knowledge from numerous leadership positions in operations and
engineering. His experience will be a great addition to our already
robust board."

Tanaka joined Johnson & Johnson in 1997 as the U.S. president of
Biosense Webster, Inc. before being named to the position of worldwide
president. From 1992 to 1997, he served in a variety of senior
management positions at Sorin Biomedical Inc., including president and
chief executive officer. From 1989 to 1992, Tanaka served in vice
president roles with Shiley, a division of Pfizer Incorporated. Tanaka
received a bachelor of science degree in mechanical engineering from
Purdue University and an MBA from Illinois Benedictine College.

Regarding his appointment, Tanaka said, "TomoTherapy is a proven
technology leader in the field of image-guided radiotherapy for cancer
patients. I am excited to join the board and work with the management
team to expand our global presence."

Tanaka replaces John P. Neis who retired from the TomoTherapy
board effective August 31, 2008. Neis is the co-founder and managing
director of Venture Investors LLC, which participated in several
rounds of venture capital financing for TomoTherapy.

Said Robertson, "We say goodbye to John with deep appreciation for
his years of dedication to TomoTherapy and our mission. He was with us
as we moved from concept to manufacturing to a publicly-held company.
We know other companies will benefit from his counsel going forward."

Neis served on the TomoTherapy audit, compensation, and nominating
and governance committees. On September 1, 2008, Tanaka was appointed
to the audit committee. Current board member Frances Taylor is now
serving on the nominating and governance committee while John Greisch
recently joined the compensation committee.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation
therapy system for the treatment of a wide variety of cancers. The
Hi-Art treatment system combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with
speed and precision while reducing radiation exposure to surrounding
healthy tissue. The company's stock is traded on the NASDAQ Global
Select Market under the symbol TOMO. To learn more about TomoTherapy,
please visit TomoTherapy.com.

(C)2008 TomoTherapy Incorporated. All rights
reserved. TomoTherapy, CTrue, the TomoTherapy logo and Hi-Art are
among trademarks, service marks or registered trademarks of
TomoTherapy Incorporated.

TomoTherapy Incorporated
Investor Contact:
Stephen C. Hathaway
Chief Financial Officer
608.824.2800
shathaway@tomotherapy.com
or
Media Contact:
Patty Kitowski
Marketing Communications Manager
608.824.2820
pkitowski@tomotherapy.com

Copyright Business Wire 2008